LINC01793: A Potential Drug Target and Biomarker (G101927285)

Target Name: LINC01793

NCBI ID: G101927285

LINC01793

Other Name(s): Long intergenic non-protein coding RNA 1793 | long intergenic non-protein coding RNA 1793

LINC01793: A Potential Drug Target and Biomarker

Non-protein coding RNAs (ncRNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These small RNAs play a crucial role in gene regulation and are involved in the regulation of various cellular processes. One of the most promising classes of ncRNAs is the long intergenic non-protein coding RNAs (long INs), which have been identified in a wide range of organisms. In this article, we will focus on LINC01793, a long IN that has potential as a drug target and biomarker.

LINC01793 is a 21-kDa RNA molecule that is located between the intron-exon boundaries of genes. It is characterized by a unique structure that consists of a hairpin-like terminal end that is composed of a single nucleotide and a loop region that is composed of multiple nucleotides. LINC01793 is expressed in various tissues and cells, including brain, heart, and pancreas, and has been shown to be involved in the regulation of gene expression.

One of the key features of LINC01793 is its ability to interact with other RNA molecules. LINC01793 has been shown to interact with several different RNA molecules, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and protein coding RNAs (pcRNAs). These interactions play a crucial role in the regulation of gene expression and are being targeted as potential drug targets.

In addition to its potential as a drug target, LINC01793 also has potential as a biomarker. The expression of LINC01793 has been shown to be regulated by various factors, including gene expression, RNA binding, and post-transcriptional modifications. This makes LINC01793 an attractive candidate for use as a biomarker for various diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases.

Another promising aspect of LINC01793 is its expression pattern. LINC01793 has been shown to be expressed in a variety of tissues and cells, including brain, heart, and pancreas. Its expression has also been shown to be regulated by various factors, including gene expression, RNA binding, and post-transcriptional modifications. These properties make LINC01793 an attractive candidate for use as a diagnostic tool for various diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases.

In conclusion, LINC01793 is a long IN with potential as a drug target and biomarker. Its unique structure and interactions with other RNA molecules make it an attractive candidate for use as a potential drug. Additionally, its expression pattern and regulation by various factors make it an attractive candidate for use as a diagnostic tool for various diseases. Further research is needed to fully understand the potential of LINC01793 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1793

The "LINC01793 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01793 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets